第四章。化学,制造和控制:活性药物成分和药品

Prem Ramiya
{"title":"第四章。化学,制造和控制:活性药物成分和药品","authors":"Prem Ramiya","doi":"10.1039/9781788016445-00097","DOIUrl":null,"url":null,"abstract":"Chemistry, manufacturing and controls (CMC) for active pharmaceutical ingredients (APIs) and drug products (DPs) consists in understanding the chemistry behind the manufacturing process, in-process controls, acceptance criteria for drug substances and DPs and supporting stability studies. Guidance documents from the US Food and Drug Administration (FDA) and International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) assist novice readers with how to implement most of the CMC-related activities during development and commercialization activities. The development process for APIs and DPs follows the traditional approach of preclinical, Phase I (safety), Phase II (efficacy) and Phase III (statistical significance over existing therapy) and then final approval after filing a New Drug Application (NDA) by the FDA or marketing approval in the European Union (EU). This chapter (a) summarizes the CMC topics for APIs and DPs in general and (b) narrates the distinct activities required in each phase of development as the molecule progresses from early development to commercialization.","PeriodicalId":20009,"journal":{"name":"Peptide Therapeutics","volume":"7 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chapter 4. Chemistry, Manufacturing and Controls: Active Pharmaceutical Ingredient and Drug Product\",\"authors\":\"Prem Ramiya\",\"doi\":\"10.1039/9781788016445-00097\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Chemistry, manufacturing and controls (CMC) for active pharmaceutical ingredients (APIs) and drug products (DPs) consists in understanding the chemistry behind the manufacturing process, in-process controls, acceptance criteria for drug substances and DPs and supporting stability studies. Guidance documents from the US Food and Drug Administration (FDA) and International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) assist novice readers with how to implement most of the CMC-related activities during development and commercialization activities. The development process for APIs and DPs follows the traditional approach of preclinical, Phase I (safety), Phase II (efficacy) and Phase III (statistical significance over existing therapy) and then final approval after filing a New Drug Application (NDA) by the FDA or marketing approval in the European Union (EU). This chapter (a) summarizes the CMC topics for APIs and DPs in general and (b) narrates the distinct activities required in each phase of development as the molecule progresses from early development to commercialization.\",\"PeriodicalId\":20009,\"journal\":{\"name\":\"Peptide Therapeutics\",\"volume\":\"7 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Peptide Therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1039/9781788016445-00097\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Peptide Therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/9781788016445-00097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

原料药(api)和原料药(dp)的化学、生产和控制(CMC)包括了解生产工艺背后的化学、过程控制、原料药和dp的验收标准以及支持稳定性研究。来自美国食品和药物管理局(FDA)和国际人用药品注册技术要求协调委员会(ICH)的指导文件帮助新手读者在开发和商业化活动期间如何实施大多数cmc相关活动。原料药和DPs的开发过程遵循传统的临床前、I期(安全性)、II期(有效性)和III期(现有治疗的统计显著性)的方法,然后在向FDA提交新药申请(NDA)或在欧盟(EU)获得上市批准后获得最终批准。本章(a)总结了原料药和DPs的CMC主题,(b)叙述了分子从早期开发到商业化过程中每个开发阶段所需的不同活动。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Chapter 4. Chemistry, Manufacturing and Controls: Active Pharmaceutical Ingredient and Drug Product
Chemistry, manufacturing and controls (CMC) for active pharmaceutical ingredients (APIs) and drug products (DPs) consists in understanding the chemistry behind the manufacturing process, in-process controls, acceptance criteria for drug substances and DPs and supporting stability studies. Guidance documents from the US Food and Drug Administration (FDA) and International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) assist novice readers with how to implement most of the CMC-related activities during development and commercialization activities. The development process for APIs and DPs follows the traditional approach of preclinical, Phase I (safety), Phase II (efficacy) and Phase III (statistical significance over existing therapy) and then final approval after filing a New Drug Application (NDA) by the FDA or marketing approval in the European Union (EU). This chapter (a) summarizes the CMC topics for APIs and DPs in general and (b) narrates the distinct activities required in each phase of development as the molecule progresses from early development to commercialization.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Peptide Therapeutics: Fundamentals of Design, Development, and Delivery Chapter 5. Peptide Manufacturing Methods and Challenges Chapter 2. Regulatory Perspective on Synthetic Peptides in Europe Chapter 13. Assessing the Impact of Functional Excipients on Peptide Drug Product Attributes During Pharmaceutical Development Chapter 9. Impurity Characterization and Quantification by Liquid Chromatography–High-resolution Mass Spectrometry
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1